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Abstract: 
Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) based on three 
dimensional quantitative structure–activity relationship (3D-QSAR) studies were conducted on a series (78 compounds) of 2, 4-diamino-5-
methyl-5-deazapteridine (DMDP) derivatives as potent anticancer agents. The best prediction were obtained with a CoMFA standard 
model (q
2 = 0.530, r
2 = 0.903) and with CoMSIA combined steric, electrostatic, hydrophobic and hydrogen bond donor fields (q
2 = 0.548, r
2 
= 0.909). Both models were validated by a test set of ten compounds producing very good predictive r
2 values of 0.935 and 0.842, 
respectively. CoMFA and CoMSIA contour maps were then used to analyze the structural features of ligands to account for the activity in 
terms of positively contributing physiochemical properties such as steric, electrostatic, hydrophobic and hydrogen bond donor fields. The 
resulting contour maps produced by the best CoMFA and CoMSIA models were used to identify the structural features relevant to the 
biological activity in this series of analogs. This study suggests that the highly electropositive substituents with low steric tolerance are 
required at 5 position of the pteridine ring and bulky electronegatve substituents are required at the meta-position of the phenyl ring. The 
information obtained from CoMFA and CoMSIA 3-D contour maps can be used for the design of deazapteridine-based analogs as 
anticancer agents. 
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Background: 
The enzyme dihydrofolate reductase (DHFR) (5, 6, 7, 8 - 
tetrahydrofolate, NADP
+ oxido-reductase EC 1.5.1.3), utilizing 
NADPH as a cofactor, catalyzes the reduction of dihydrofolate to 
tetrahydrofolate. Tetrahydrofolate and its derivatives are essential 
cofactors in the synthesis of thymidylate, purines and some 
amino-acids. Inhibition of DHFR results in the depletion of 
reduced folate pools, inhibition of DNA synthesis, and cell death. 
Therefore, DHFR has proven to be an important target in cancer 
therapy. Methotrexate (MTX), a tight binding inhibitor of DHFR, 
is used to treat patients with leukemia and solid tumors in addition 
to a variety of other non-malignant diseases. The anti-folate 
methotrexate has been rationally-designed nearly 60 years ago to 
potently block the folate-dependent enzyme DHFR thereby 
achieving temporary remissions in childhood acute leukemia. 
 
DHFR is not a new target. However, there is active enthusiasm for 
the development of improved derivatives for DHFR specific 
inhibitor [1-6]. A unique feature of DHFR is the selectivity that is 
possible in the design of inhibitors. This makes it an ideal yet old 
target for rational and effective design for anticancer agents. The 
anti-folate compounds evaluated in this investigation are 
derivatives of DMDP, having structures similar to the 
trimetrexate/piritrexim class of anti-folates. Due to an interest in 
new anticancer drugs, several DMDP inhibitors were chosen from 
the Southern Research Institute chemical repository for screening 
against human DHFR. [7]. A sound understanding of the 
structural requirements for anticancer activity in DMDP is 
important in guiding and optimizing drug design efforts. 
However, there is no comprehensive structure activity relationship 
study of DHFR in the literature. 
  
QSAR based on the 3D structures of ligands involve two methods 
namely CoMFA [8] and CoMSIA [9]. Recently, more advanced 
techniques have attempted to model the receptor environment for 
accommodating ligand structure. QSAR studies incorporate 3D 
data for ligands and provide a more detailed analysis of ligand-
receptor interactions. Here, we describe 3D QSAR studies of 78 
CoMFA and CoMSIA. Thus, the resulting CoMFA and CoMSIA 
studies will not only illustrate the conformation or spatial 
orientation of anti-cancer DMDP derivatives but also provide 
useful indicators for the design of new drug candidates for cancer. 
These results are applicable to the prediction of the activities of 
new DHFR inhibitors and provide structural implications for 
designing potent and selective DHFR inhibitors as anticancer 
agents. 
 
Methodology: 
Molecular structures and optimization 
Seventy eight molecules selected for the present study were taken 
from an earlier report (7). The structures of the compounds and 
their biological data are given in Table 1 (see supplementary 
material). The IC50 values were converted to the corresponding 
pIC50 (-logIC50) and used as dependent variables in CoMFA and 
CoMSIA analysis. The pIC50 values span a range of 3-log units 
providing a broad and homogenous data set for 3D-QSAR study. 
The 3D QSAR models were generated using a training set of 68 Bioinformation by Biomedical Informatics Publishing Group                                                 open access 
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molecules. Predictive power of the resulting models was 
evaluated using a test set of 10 molecules (molecule denoted as 
bold in Table 1 under supplementary material). The test 
compounds were selected manually such that the structural 
diversity and wide range of activity in the data set were included. 
 
Molecular alignment 
CoMFA results may be extremely sensitive to a number of factors 
such as alignment rules, overall orientation of the aligned 
compounds, lattice shifting step size and probe atom type [10]. 
The accuracy of prediction of CoMFA models and the reliability 
of the contour models depend strongly on the structural alignment 
of the molecules [10]. Thus, we applied molecular alignment to 
align all the molecules used in the present study. The molecular 
alignment was achieved by SYBYL routine database align. The 
most active compound (compound 63) was used as an alignment 
template and the rest of the molecules were aligned to it by using 
the common substructure. Partial atomic charges were calculated 
using the MMFF94 charges. 
           
CoMFA studies 
Steric and electrostatic interactions were calculated using the 
Tripos force field [11] with a distance-dependent dielectric 
constant at all interactions in a regularly spaced (2Å) grid taking a 
sp
3 carbon atom as steric probe and a
+1 charge as electrostatic 
probe. The cutoff was set to 30kcal/mol. With standard options for 
scaling of variables, the regression analysis was carried out using 
the fully cross-validated partial least squares (PLS) method (leave 
one out) [12]. The minimum sigma (column filtering) was set to 
2.0 kcal/mol to improve the signal to noise ratio by omitting those 
lattice points whose energy variation was below this threshold. 
The final model which is non cross-validated conventional 
analysis was developed with the optimum number of components 
to yield a non cross-validated r
2 value. 
 
CoMSIA studies             
In CoMSIA, a distance-dependent Gaussian-type physicochemical 
property has been adopted to avoid singularities at the atomic 
positions and dramatic changes of potential energy for those grids 
in the proximity of the surface. With the standard parameters and 
no arbitrary cutoff limits, three physico-chemical properties, 
namely, steric, electrostatic and hydrophobic fields were 
calculated. The steric contribution was reflected by the third 
power of the atomic radii of the atoms. Electrostatic properties 
were introduced as atomic charges resulted from molecular 
docking. An atom-based hydrophobicity was assigned according 
to the parameterization developed by Ghose and colleagues [13]. 
The lattice dimensions were selected with a sufficiently large 
margin (>4Å) to enclose all the binding conformations of the 
inhibitors. In general, similarity indices, AF,K between the 
compounds of interest were computed by placing a probe atom at 
the intersections of the lattice points using Equation 1 (see 
supplementary material).   
 
In the present study, similarity indices were computed using a 
probe atom (Wprobe,k) with charge +1, radius 1Å, hydrophobicity 
+1, and attenuation factor a of 0.3 for the Gaussian type distance. 
The statistical evaluation for the CoMSIA analyses was performed 
in the same way as described for CoMFA. 
Partial least square (PLS) analysis 
PLS method (8) was used to linearly correlate the CoMFA fields 
to biological activity values. The cross-validation was performed 
using leave-one-out (LOO) method in which one compound is 
removed from the dataset and its activity is predicted using the 
model derived from the rest of the molecules in the dataset. Equal 
weights for CoMFA were assigned to steric and electrostatic 
fields using CoMFA STD scaling option. To speed up the analysis 
and to reduce noise, a minimum column filter value of 2.0 
kcal/mol was used for the cross-validation. Non-cross-validation 
was performed to calculate conventional r
2 using the same number 
of components. To further assess the robustness and statistical 
confidence of the derived models, bootstrapping analysis for 100 
runs was performed (14) and (15). Bootstrapping involves the 
generation of many new data sets from original dataset and is 
obtained by randomly choosing samples from the original dataset. 
The statistical calculation is performed on each of these 
bootstrapping samplings. The difference between the parameters 
calculated from the original dataset and the average of the 
parameters calculated from many bootstrapping samplings is a 
measure of the bias of the original calculations. The entire cross-
validated results were analyzed considering the fact that a value of 
q
2 above 0.3 indicates that probability of chance correlation is less 
than 5% [14]. 
 
Hardware and software 
Insight II 2000.1 (16) and Sybyl 7.1 (17) were used for molecular 
modeling on a SGI Origin 300 workstation equipped with 4 * 600 
Mhz R12000 processors. 
 
Discussion: 
3D QSAR STUDIES 
CoMFA and CoMSIA 3D-QSAR models were derived using 
previously reported DHFR inhibitors. The chemical structures of 
molecules and their experimental pIC50 values are given in Table 
1 (see supplementary material). 
 
CoMFA analysis 
Sixty eight compounds out of the total seventy eight DHFR 
inhibitors were used as training set and ten compounds were used 
as test set. The test set compounds were selected manually so that 
the structural diversity and wide range of activity in the dataset 
were included. PLS analysis was carried out for the training set 
and a cross-validated q
2 of 0.530 for six components was 
obtained. The non cross-validated PLS analysis with the optimum 
components revealed a conventional r
2 value of 0.903, F = 94.349 
and an estimated standard error of prediction (SEP) 0.386. The 
steric field descriptors explain 52.2 % of the variance, while the 
electrostatic descriptors explain 47.8 % of the variance. Bootstrap 
analysis for 100 runs was then carried out for further validation of 
the model by statistical sampling of the original dataset to create 
new datasets.  
 
Thus, the difference in the parameters calculated from the original 
data and the average of the parameters calculated from the 
N(=100) runs of bootstrapping sampling is a measure of the bias 
of the original calculation. This yielded higher r
2
bootstrap value 
0.939 for CoMFA with standard error value of 0.299. This further 
supports the statistical validity of the developed models. The Bioinformation by Biomedical Informatics Publishing Group                                                 open access 
www.bioinformation.net                                                                         Hypothesis 
_________________________________________________________________________________________________ 
ΙSSN 0973-2063                                                                            
Bioinformation 2(9): 384-391 (2008) 
Bioinformation, an open access forum 
© 2008 Biomedical Informatics Publishing Group 
386
predicted activities for the inhibitors versus their experimental 
values are listed in Table 1 (see supplementary material) and the 
correlation between the predicted activities and the experimental 
values is depicted in Figure 1. Figure 1 illustrate the predicted 
activities using the CoMFA model are in good agreement with the 
experimental data, suggesting that the CoMFA model should have 
a satisfactory predictive ability. 
 
CoMSIA analysis 
The CoMSIA analyses were performed using four descriptor 
fields: steric, electrostatic, hydrophobic and hydrogen bond donor. 
The CoMSIA study revealed a cross validated q
2 of 0.548 with 
optimum number of component 6, a conventional r
2 of 0.909 with 
a standard error of 0.373 and F = 101.992 for training set. The 
steric field descriptor explains 17.4 % of the variance and, the 
electrostatic descriptor explains 43.0 %, the hydrophobic field 
explains 28.4% while the hydrogen bond donor explains 11.4 % 
of the variance. Bootstrap analysis for 100 runs was then carried 
out for further validation of the model by statistical sampling of 
the original dataset to create new datasets. Thus, the difference in 
the parameters calculated from the original data and the average 
of the parameters calculated from N(=100) runs of bootstrapping 
sampling is a measure of the bias of the original calculation. This 
yielded higher r
2
bootstrap value 0.939 for CoMSIA with standard 
error value of 0.297 supporting the statistical validity of the 
developed models. The predicted inhibitory activities are listed in 
Table 1 (see supplementary material). The correlation between the 
experimental and predicted bioactivities is shown in Figure 1. 
Results show that prediction by the CoMSIA model is reasonably 
accurate. 
 
 
Figure 1: 1(a) and 1(b) are the predictive versus experimental pIC50 values derived from CoMFA and CoMSIA model for training set 
(black hole) and test set (white rectangle).
 
Figure 2d displays the hydrogen bond donor contour maps 
represented by cyan and purple contours. Cyan contours indicate 
regions where hydrogen bond donor substituents on ligands are 
favored and purple contours represent areas where hydrogen bond 
donor properties on inhibitors are disfavored. However, in our 
CoMSIA analysis hydrogen bond donor field do not have effect 
on the variance. Therefore, we found only two cyan contours in 
the hydrogen bond donor maps near the NH2 group in 
deazaptredine ring of compound 63, indicating that hydrogen 
bond donor functionalities in this region will enhance the activity 
(Figure 2d). In summary, the CoMFA and CoMSIA models for 
anticancer activity indicated that highly electropositive 
substituents with low steric tolerance are required at position 5 of 
the pteridine ring and bulky electronegative substituents are 
required at meta position of the phenyl ring. 
 
Validation of 3D-QSAR models 
The ten manually selected compounds (Table 1 in supplementary 
material) were used as testing set to verify the stability and 
predictive ability of the CoMFA and CoMSIA models. The 
predicted pIC50 with the QSAR models are in good agreement 
with the experimental data within a statistically tolerable error 
range, with a predicted correlation coefficient of rpred
2 = 0.935 and 
0.842 and standard error of prediction value 0.244 and 0.380 for 
CoMFA and CoMSIA, respectively. The correlation between 
CoMFA and CoMSIA predicted activities and the experimental 
activities of the testset compounds are depicted in Figure 1. The 
testing results indicate that the CoMFA and CoMSIA models can 
be reliably used in the design of novel DHFR inhibitors. 
 
Contour analysis 
The visualization of the results of the CoMFA and CoMSIA 
models have been performed using the StDev*Coeff mapping 
option contoured by contribution. The default level of contour 
with contribution, 80% for favored region and 20% for disfavored 
region was set during contour analysis. 
 
CoMFA contour maps 
CoMFA steric and electrostatic contours are shown in Figures 2. 
The steric interaction is represented by green and yellow contours, 
while electrostatic interaction is denoted by red and blue contours. 
A large yellow contour is located around the O-methyl substituted 
phenyl ring of compound 29 and –CH2OCH3 on the 5-position of 
the pteridine ring suggesting that groups with low steric tolerance 
are required at this position to increase the activity (Figure 2a). 
This is possibly a reason why, compounds 45, 50 and 51 are less 
potent. In case of compound 63, large green contour was found 
near the plane of Chloro substituted napthyl ring of compound 
indicating that bulky substituents were preferred in this region 
(Figure 2b). Similarly, in compound 41 bromo group extends 
towards the large green contour which is the favorable region for 
bulkier groups and hence compound 41 is high in binding affinity. Bioinformation by Biomedical Informatics Publishing Group                                                 open access 
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This may be the reason why compounds with large aromatic 
substituents in this area, e.g. compounds 59, 60, 61, 62, 63, 64, 65 
and 66 are more potent than molecules with smaller substituents, 
such as compounds 29, 32, 45, 50 and 51. 
 
The CoMFA electrostatic contour plot is displayed in Figure 2a 
and Figure 2b. A blue contour indicate that substituents should be 
electron deficient for high binding affinity and red color indicates 
that substituents should be electron rich for high binding affinity 
with the protein. A red contour was found overlapping –
CH2OCH3 substitution at 5-position of compound 29 with an 
electron rich functionality and hence compound 29 exhibit low 
activity (Figure 2a). Similarly in case of other low active 
compounds like compounds 50 and 51 the substitution of –
CH2OCH3 at 5-position overlaps blue contour which is a favorable 
region for electron deficient moieties and thus lead to decrease in 
the activity. In contrast, compound 63, most potent inhibitor, has 
no functional group with high electron density extended to the 
blue areas (Figure 2b). Similarly, other highly active compounds 
like compound 41, 46, 47, 48, 49, 50, 64 and 66 have no electron 
rich substituents at 5-position of the pteridine ring and hence these 
molecules are having greater binding affinity towards human 
DHFR. A red contour was found near the Chloro substituted 
napthyl ring of compound 63 indicating a preference for 
negatively charged substituents in these areas (Figure 2b). The 
presence of negative charges favored red contours near the 
napthyl ring and this indicates the addition of electron rich groups 
may increase high binding affinity.  
 
CoMSIA contour maps 
The contours maps of CoMSIA were derived using steric, 
electrostatic, hydrophobic and hydrogen bond donor fields. 
CoMSIA steric and electrostatic are more or less similar to those 
of CoMFA steric and electrostatic contour maps. In CoMFA, a 
large green contour was found overlapping the plane of Chloro 
substituted napthyl ring of compound 63,  indicating that bulky 
substituents were preferred in this region. Similarly, in case of 
another highly active compound 41, green contour overlaps with 
methyl and Bromo substituted phenyl ring which indicates that 
bulkier groups are preferred in this region. A large yellow contour 
is found overlapping the O-methyl substitution at 2-position of the 
phenyl ring in case of compound 29 which is the region where 
bulkier substituents are not preferred and that is why compounds 
having bulkier substituents extended to this region and hence 
compounds 1, 2, 3, 6, 7, 8, 29, 54 and 67 are either less active or 
moderate active. There is one red contour overlapping the –NH 
group compound 29, which means that this group is not favored in 
this region and will lead to decrease in the inhibitory potency. 
Similarly, in compound 78, a blue contour was found overlapping 
the –O(CH2)2CH3  and this leads to decrease in  activity for 
compound 78. 
 
Hydrophobic contour map from CoMSIA is shown in Figure 2c. 
Hydrophobic region is represented by white contours and 
unfavorable regions are represented by yellow contours. CoMSIA 
hydrophobic contour map showed a big white contour covering 
chloro substituted napthyl ring of compound 63, suggesting that 
increase in hydrophobicity in this region is expected to improve 
the activity of molecule (Figure 2c). A small yellow contour 
covers the –CH3 group of compound 63 indicating that 
hydrophobic substituents are not preferred in this region. Further 
increase in hydrophobicity at this position will bring down the 
activity, that is why 63 is more active than the 29, 45, 50 and 51. 
Substituents which decrease the net hydrophobicity of the moiety 
like NH2 may lead to increase in the activity of the molecule.  
 
 
Figure 2: 2(a) and 2(b) are steric and electrostatic contour maps of CoMFA and CoMSIA model for low active compound 29 and high 
active compound 63 respectively. The favorable steric areas (contribution level 80%) with more bulkiness are indicated by green isopleths 
and the dis-favorable steric areas (contribution level 20%) are shown by yellow isopleths. The favorable electrostatic areas (contribution 
level 80%) with positive charges are indicated by blue isopleths and the favorable electrostatic areas (contribution level 20%) with negative 
charges are shown by red isopleths. 2(c) and 2(d) are the hydrophobic contour maps and hydrogen-bond contour maps of CoMSIA model 
for high active compound 63, respectively. The favorable hydrophobic areas (contribution level 80%) indicated by yellow isopleths and 
the disfavorable hydrophobic areas (contribution level 20%) are shown by white isopleths. The hydrogen bond contour maps of CoMSIA 
model are also shown. Cyan isopleths contour maps (contribution level 80%) beyond the ligands where a hydrogen - bond donor group in 
the ligand will be favorable for biological activity and purple isopleths (contribution level 20%) represents hydrogen - bond acceptor in the 
ligands unfavorable for bioactivity. Bioinformation by Biomedical Informatics Publishing Group                                                 open access 
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Conclusion: 
In this study, 3-D CoMFA and CoMSIA QSAR analyses were 
used to predict the anticancer activity of a set of DMDP 
derivatives. The QSAR models gave good statistical results in 
terms of q
2 and r
2 values. The CoMFA model provided significant 
correlation of steric and electrostatic fields with biological activity 
values. The effects of steric, electrostatic, hydrophobic and 
hydrogen-bond donor fields around the aligned molecules on 
biological activity were clarified by analyzing the CoMSIA 
contour maps. The information obtained in this study provides a 
methodology for predicting the affinity of related DMDP 
compounds for guiding structural design of novel yet potent 
anticancer agents. 
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DMDP derivatives with modifications 
N
N N
N
NH2
NH2
H
R6
R5
R4
R3 R2
R1
 
DMDP derivatives with modifications at the 5 position (R1) and substitutions on the 
phenyl group (R2 through R6). 
Derivative 
no. 
R1 R2  R3  R4  R5  R6 
Exp. 
Activity 
(-log IC50) 
Predicte
d 
Activity 
(CoMFA
) 
Predicted 
Activity 
(CoMSI
A) 
Comp. 1  -CH3 -OCH2CH3 -H  -H -OCH2CH3 -H  5.638 5.702  6.005 
Comp. 2  -CH3 -OCH3 -H  -H -OCH3 -H 6.000  5.966  6.364 
Comp. 3  -CH3 -OCH3CH3 -H  -H -OCH2CH3 -H  6.00 5.501  5.489 
Comp. 4  -CH3 -CH3 -H -H  -OCH3 -H 6.824  7.349  7.267 
Comp. 5  -CH3 -CH3 -H  -Br  -H -CH3 5.721  6.596  6.373 
Comp. 6  -CH2CH3 -OCH3 -H  -H -OCH3 -H 6.000  5.437  6.097 
Comp. 7  -CH3 -OCH3 -H  -H  -CH3 -H  6.523  6.976  6.691 
Comp. 8  -CH3 -OCHF2 -H  -H  -H  -H  6.558  6.678  6.947 
Comp. 9  -CH3 -F  -H  -H  -CH3 -H  6.602  6.979  7.160 
Comp. 10  -CH3 -Cl  -H  -CH3 -H -CH3 6.071  6.602  6.382 
Comp.  11  -CH3  -Cl -H  -H -H -H  6.921  7.231  7.134 
Comp. 12  -CH2CH3 -OCH3 -H  -H  -CH3 -H  6.432  7.005  6.508 
Comp. 13  -CH3 -F  -H  -H  -F  -H  7.161  7.462  7.492 
Comp. 14  -CH3 -OCH3 -H  -C6H5 -H  -H 7.167  7.379  7.000 
Comp. 15  -CH3 -CH3 -H -H -CH3 -H  7.244  7.584  7.155 
Comp. 16  -CH3 -Cl  -H  -H  -CH3 -H  7.357  7.034  7.043 
Comp. 17  -CH3  -Cl  -H  -F  -CH3 -H  7.481  7.836  7.739 
Comp. 18  -CH3 -H  -H  -Cl  -H  -H  7.569  7.626  7.960 
Comp. 19  -CH3 -OCH3 -H  -H  -CF3 -H  7.444  7.401  7.254 
Comp. 20  -CH3 -H  -OCH3 -H  -OCH3 -H 7.824  6.978  7.217 
Comp. 21  -CH3 -CH3 -H -H  -F  -H  7.721  7.816  7.835 
Comp. 22  -CH3  -H  -Cl  -H  -H  -H  7.77  7.879  7.866 
Comp. 23  -CH3 -H  -H  -OCHF3 -H  -H  7.699  7.458  8.464 
Comp. 24  -CH3 -H  -OCH3 -OCH3CH3 -H  -H  7.553 7.691  7.669 
Comp. 25  -CH3 -H  -OCH3 -O(CH3) 
3CH3 
-H -H  7.824  7.904  7.907 
Comp. 26  -H  -H  -OCH3 -OCH3 -OCH3 -H 5.409  5.695  5.714 
Comp. 27  -CH3 -H  -F  -OCH3 -H  -H 7.854  7.671  8.174 
Comp. 28  -CH3 -CH3 -H  -Cl  -H  -H  8.553  8.441  7.768 
Comp. 29  -CH2OCH3 -OCH3 -H  -H -OCH3 -H 4.509  4.580  4.352 
Comp. 30  -CH3 -H  -OCH3 -H  -OCH3 -H 8.060  8.148  7.671 
Comp. 31  -CH3 -OCH3 -H -Cl -CH3 -H  8.000  7.545  7.338 
Comp. 32  -H  -H  -H  -Cl  -H  -H  6.174  5.750  6.266 
Comp. 33  -CH3 -Cl  -H  -H  -Cl  -H  8.097  8.127  7.806 
Comp. 34  -CH3 -CH3 -H -H  -Cl  -H  8.215  7.899  7.858 
Comp. 35  -CH3 -H  -Cl  -CH3 -H  -H  8.174  8.199  8.172 
Comp. 36  -CH3 -H  -OCH3 -OCH3 -H  -H 8.292  7.619  7.576 
Comp. 37  -CH3  -H  -CH3 -Br  -H  -H  8.215  7.873  7.759 
Comp. 38  -CH3 -CH3 -H  -Br  -H  -H  8.229  8.470  7.840 
Comp. 39  -CH3 -Br  -H  -H  -Br  -H  8.337  7.929  7.825 
Comp. 40  -CH3 -CH3 -Cl -H  -H  -H  8.284  8.308  8.152 
Comp. 41  -CH3 -H  -Br  -CH3 -H  -H  8.432  8.361  8.181 
Comp. 42  -CH3  -H  -OCH3 -H  -CF3 -H  8.260  8.709  8.346 
Comp. 43  -CH3 -H  -OCH3 -OCH3 -OCH3 -H 8.328  7.667  7.555 
Comp. 44  -CH3  -H -Cl  -Cl -H -H  8.301  8.574  8.660 
Comp. 45  -CH2OCH3 -H -OCH3 -OCH3 -H  -H 5.215  5.593  5.325 
Comp. 46  -CH3 -F  -H  -H  -CF3 -H  8.387  8.198  8.596 Bioinformation by Biomedical Informatics Publishing Group                                                 open access 
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Comp. 47  -CH3 -OCH3 -H  -H  -CF3 -H  8.569  8.666  8.388 
Comp. 48  -CH2CH3 -OCH3 -H  -H  -CF3 -H  8.444  8.010  8.115 
Comp. 49  -CH3 -Br  -H  -H  -CF3 -H  8.495  8.134  8.200 
Comp. 50  -CH2OCH3 -H -OCH3 -OCH3 -OCH3 -H 5.886  5.711  5.157 
Comp. 51  -CH2OCH3 -H  -H -Cl  -H  -H 5.585  5.514  5.709 
 
N
N N
N
H
X
NH2
NH2
CH3
 
DMDP derivatives with Complex ring substitutions attached to the CN Bridge. 
  
  X     
Comp. 52 
 
6.149 6.344  6.207 
Comp. 53 
 
6.848 7.252  6.841 
Comp. 54 
 
5.276 4.836  5.102 
Comp. 55 
 
8.000 7.835  7.767 
Comp. 56 
 
5.469 5.267  5.403 
Comp. 57 
N
 
7.921 7.835  7.767 
Comp. 58 
 
6.086 5.864  6.419 
Comp. 59 
 
8.174 8.116  8.243 
Comp. 60 
N
 
8.149 8.224  7.840 
Comp. 61 
 
8.208 8.580  8.243 Bioinformation by Biomedical Informatics Publishing Group                                                 open access 
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Comp. 62 
 
8.367 7.672  8.141 
Comp. 63  Cl
 
8.699 8.382  8.640 
Comp. 64 
N 
8.398 8.479  8.550 
Comp. 65 
N
 
8.367 8.394  8.698 
Comp. 66 
 
8.42 8.277  8.631 
Comp. 67 
 
4.596 4.976  4.557 
 
N
N N H2N
NH2 CH3
CH2 X
R6 R5
R4
R3 R2  
DMDP derivatives involving modification of the bridge molecules X 
  
  X R2  R3  R4  R5  R6     
Comp. 68  -CH3 -H  -OCH3 -H  -OCH3 -H 6.004  6.735  6.215 
Comp. 69  -S  -H  -H  -OCH3 -OCH3 -H 6.357  6.089  6.771 
Comp. 70  -S  -H  -OCH3 -OCH3 -OCH3 -H 5.921  6.634  6.805 
Comp. 71  -S  -H  -H  -H  -OCH3 -H 6.301  6.635  6.544 
Comp. 72  -S  -H  -H  -Cl  -H  -H  6.229  6.586  6.852 
Comp. 73  -S  -OCH3 -H  -H -OCH3 -H 5.602  5.564  5.459 
Comp. 74  -S  -H  -H  -H  -Cl  -H  6.377  6.626  6.372 
Comp. 75  -S      -1-Naphthyl      6.357  6.149  6.099 
Comp. 76  -CH3 -OCH3 -H  -H -OCH3 -H 5.569  5.881  5.419 
Comp. 77  -S  -H  -H  -H  -CH3 -H  6.071  6.280  6.138 
 
N
N N H2N
NH2 CH3
N
H
R2
R5
 
 
DMDP derivatives in the series involving substitutions at the R2 and R5 positions. 
  
  R2 R2     
Comp.78 -O(CH2) 2CH3 -O(CH2) 2CH3 5.137  5.077  5.439 
Table 1: DMDP derivatives with modifications with experimental and predictive activity (* bold are test compounds). 